You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Neoplasm by Histologic Type

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Dupuytren Contracture, Dupuytren's Disease, Contracture Trial (procedure, drug, other)

Not yet recruiting
  • Dupuytren Contracture
  • +11 more
  • Percutaneous needle fasciotomy
  • +2 more
  • (no location specified)
Jun 30, 2022

Cervical Intraepithelial Neoplasia Grade 2/3, Tumor Cervix, Carcinoma in Situ Trial in Milan (Self-Collecting Devices, In Vitro

Completed
  • Cervical Intraepithelial Neoplasia Grade 2/3
  • +5 more
  • Self-Collecting Devices
  • In Vitro Diagnostic Assays
  • Dublin, Ireland
  • +5 more
Jan 5, 2023

Tumors, Tumors, Glandular and Epithelial, Tumors by Histologic Type Trial in San Antonio (Entinostat, Placebo)

Completed
  • Neoplasms
  • +14 more
  • San Antonio, Texas
    The START Center for Cancer Care
Apr 21, 2022

Lung Tumor Malignant, NSCLC, Respiratory Tract Tumors Trial in United States (BLU-451)

Recruiting
  • Lung Neoplasm Malignant
  • +18 more
  • Fairfax, Virginia
    New Experimental Therapeutics of Virginia (NEXT Oncology)
Mar 29, 2022

Tumors, Tumors, Glandular and Epithelial, Tumors by Histologic Type Trial in San Antonio (Entinostat, Pembrolizumab)

Completed
  • Neoplasms
  • +13 more
  • San Antonio, Texas
    The START Center for Cancer Care
Jan 24, 2022

Multiple Myeloma, Tumor, Plasma Cell, Tumors by Histologic Type Trial in United States (CYNK-001)

Active, not recruiting
  • Multiple Myeloma
  • +19 more
  • CYNK-001
  • Denver, Colorado
  • +8 more
May 24, 2022

Lung Tumor, NSCLC, Respiratory Tract Tumors Trial in United States (BLU-701, osimertinib, carboplatin)

Recruiting
  • Lung Neoplasm
  • +26 more
  • Boston, Massachusetts
  • +6 more
Jun 23, 2022

Solid Tumor, Haematological Malignancy, Malignancy Trial in United Kingdom (Entrectinib)

Recruiting
  • Solid Tumor
  • +10 more
  • Belfast, United Kingdom
  • +25 more
Mar 14, 2023

Pralsetinib to Best Available Therapy in RET-Fusion Positive

Enrolling by invitation
  • RET-fusion Non Small Cell Lung Cancer
  • +16 more
    • New York, New York
    • +2 more
    Aug 9, 2021

    Solid Tumor, Haematological Malignancy, Malignant Tumor Trial in United Kingdom (Alectinib)

    Recruiting
    • Solid Tumor
    • +10 more
    • Belfast, United Kingdom
    • +25 more
    Mar 14, 2023

    Malignancy, Malignant Tumor, Lymphoproliferative Disorders Trial in United Kingdom (Atezolizumab)

    Not yet recruiting
    • Malignancy
    • +8 more
    • Belfast, United Kingdom
    • +25 more
    Mar 14, 2023

    Brain Cancer, Brain Tumor, Glioma Trial in Canada, United States (DNX-2401, pembrolizumab)

    Completed
    • Brain Cancer
    • +10 more
    • DNX-2401
    • pembrolizumab
    • Little Rock, Arkansas
    • +14 more
    Jul 13, 2021

    Orelabrutinib in Combination With Standard Treatment Regimen for

    Not yet recruiting
    • Lymphoma, Large B-Cell, Diffuse Neoplasms by Histologic Type
    • Nanjing, Jiangsu, China
      Hematological Department, People's Hospital of Jiangsu Province
    Aug 23, 2023

    AML, AML With Mutated NPM1, Hematologic Malignancy Trial (Ziftomenib, Fludarabine, Idarubicin)

    Not yet recruiting
    • AML
    • +11 more
    • (no location specified)
    Aug 14, 2023

    Respiratory Tract Diseases, Tumors, Tumors by Histologic Type Trial run by the National Cancer Institute (NCI) (Bevacizumab)

    Not yet recruiting
    • Respiratory Tract Diseases
    • +14 more
    • Bethesda, Maryland
      National Institutes of Health Clinical Center
    Apr 10, 2023

    RET-altered Non Small Cell Lung Cancer, Medullary Thyroid Cancer, RET-altered Papillary Thyroid Cancer Trial in Worldwide

    Active, not recruiting
    • RET-altered Non Small Cell Lung Cancer
    • +39 more
    • pralsetinib (BLU-667)
    • Phoenix, Arizona
    • +65 more
    Nov 10, 2022

    Glioma, Recurrence, Disease Attributes Trial (Vorasidenib)

    Available
    • Glioma
    • +10 more
    • (no location specified)
    Oct 19, 2022

    Lymphoma, Lymphoma, Non-Hodgkin, Immune System Diseases Trial in Chapel Hill (ATLCAR.CD30 cells)

    Recruiting
    • Lymphoma
    • +7 more
    • ATLCAR.CD30 cells
    • Chapel Hill, North Carolina
      Lineberger Comprehensive Cancer Center at University of North Ca
    Dec 2, 2022

    Melanoma Neuroendocrine Tumors Neuroectodermal Tumors Tumors Germ Cell and Embryonal Tumors by Histologic Type Tumors Tumors

    Not yet recruiting
    • Melanoma Neuroendocrine Tumors Neuroectodermal Tumors Neoplasms Germ Cell and Embryonal Neoplasms by Histologic Type Neoplasms Neoplasms
    • HX008 + TACE
    • +2 more
    • Beijing, Beijing, China
      Beijing Cancer hospital
    Dec 8, 2022

    Primary and Metastatic Tumors in Renal Cell Carcinoma and

    Recruiting
    • Renal Cell Carcinoma
    • +4 more
    • Immune checkpoint inhibitor targeting PD1
    • Philadelphia, Pennsylvania
      Fox Chase Cancer Center - Philadelphia
    Jan 27, 2023

    Tumor Metastasis, Blood Coagulation Disorder With Shortened Coagulation Time (Disorder), Venous Thromboembolism Trial in Tianjin

    Recruiting
    • Neoplasm Metastasis
    • +2 more
    • CGT test
    • Tianjin, Tianjin, China
      Tianjin Medical University General Hospital
    Jul 1, 2023

    Pleural Effusion, Heart Failure, Malignant Tumor Trial

    Not yet recruiting
    • Pleural Effusion
    • +7 more
      • (no location specified)
      Mar 31, 2023

      Lymphoma, Lymphoma, Mantle-Cell, Tumors by Histologic Type Trial (IM19 CAR-T cells, Cyclophosphamide, Fludarabine)

      Not yet recruiting
      • Lymphoma
      • +4 more
      • IM19 CAR-T cells
      • +2 more
      • (no location specified)
      Nov 30, 2021

      Colorectal Cancer, Liver Metastases Trial in Shanghai (mFOLFOX6 + Cetuximab, mFOLFOX 6)

      Not yet recruiting
      • Colorectal Cancer
      • Liver Metastases
      • mFOLFOX6 + Cetuximab
      • mFOLFOX 6
      • Shanghai, China
        Zhongshan hosptial, Fudan University
      Jul 14, 2023

      Esophageal Squamous Cell Carcinoma, Esophageal Tumors, Esophageal Diseases Trial (Anlotinib HCl, TQB2450)

      Not yet recruiting
      • Esophageal Squamous Cell Carcinoma
      • +10 more
      • (no location specified)
      Feb 19, 2022